Exendin-4 (Heloderma suspectum) – EIA Kit

The Exendin-4 (Heloderma suspectum) – EIA Kit (Catalog #EK-070-94) is a research reagent supplied by Phoenix Peptide under our specialized ELISA Kits – Assay Kits – RIA Kits category. This item is offered at a regular price of $617 for a package size of 96 wells.

Storage, Handling & Operational Notes

Transport & Regulatory Notes: To reduce background noise for this kit, do not add EDTA to your samples.Heparin can be used as an alternative to EDTA for this kit.

References & Citations: C-terminal site-specific PEGylated Exendin-4 analog: A long-acting glucagon like Peptide-1 receptor agonist, on glycemic control and beta cell function in diabetic db/db mice. Tang D, Tian H, Wu J, et al. J Pharmacol Sci. 2018138(1):23-30. GLP-1 receptor agonists stimulate ANGPTL8 production through the PI3K/Akt pathway in a GLP-1 receptor-dependent manner. Liu J, Yang K, Xiao W, et al. Peptides. 2018106:83-90. The use of low molecular weight protamine to enhance oral absorption of exenatide. Zhang L, Shi Y, Song Y, et al. Int J Pharm. 2018547(1-2):265-273. Replacement of the C-terminal Trp-cage of exendin-4 with a fatty acid improves therapeutic utility. Lee JG, Ryu JH, Kim SM, et al. Biochem Pharmacol. 2018151:59-68. Sustained-release study on Exenatide loaded into mesoporous silica nanoparticles: in vitro characterization and in vivo evaluation. Chen C, Zheng H, Xu J, Shi X, Li F, Wang X. Daru. 201725(1):20. In vitro and in vivo characterization of a novel long-acting GLP-1 receptor agonist, exendin-4–Fc fusion protein Lian Lu, Xiaoqing Su, Yantai Wang et al., RSC Adv., 2017,7, 54178-54187 An approach for half-life extension and activity preservation of an anti-diabetic peptide drug based on genetic fusion with an albumin-binding aptide. Kim D, Jeon H, Ahn S, Choi WI, Kim S, Jon S. J Control Release. 2017256:114-120. Population pharmacodynamic modeling of exenatide after 2-week treatment in STZ/NA diabetic rats. Chen T, Kagan L, Mager DE. J Pharm Sci. 2013102(10):3844-51. Combination therapy via oral co-administration of insulin- and exendin-4-loaded nanoparticles to treat type 2 diabetic rats undergoing OGTT. Chuang EY, Nguyen GT, Su FY, et al. Biomaterials. 201334(32):7994-8001. Exenatide-loaded PLGA microspheres with improved glycemic control: in vitro bioactivity and in vivo pharmacokinetic profiles after subcutaneous administration to SD rats. Xuan J, Lin Y, Huang J, et al. Peptides. 201346:172-9. Oral delivery of an anti-diabetic peptide drug via conjugation and complexation with low molecular weight chitosan. Ahn S, Lee IH, Lee E, Kim H, Kim YC, Jon S. J Control Release. 2013170(2):226-32. Delivery of two-step transcription amplification exendin-4 plasmid system with arginine-grafted bioreducible polymer in type 2 diabetes animal model. Kim PH, Lee M, Kim SW. J Control Release. 2012162(1):9-18. Sustained exendin-4 secretion through gene therapy targeting salivary glands in two different rodent models of obesity/type 2 diabetes. Di pasquale G, Dicembrini I, Raimondi L, et al. PLoS ONE. 20127(7):e40074. Site-specific PEGylation of exenatide analogues markedly improved their glucoregulatory activity. Gong N, Ma A-N, Zhang L-J, et al. British Journal of Pharmacology. 2011163(2):399-412. Pharmacokinetic and Pharmacodynamic Modeling of Exendin-4 in Type 2 Diabetic Goto-Kakizaki Rats. Gao W, Jusko WJ. The Journal of Pharmacology and Experimental Therapeutics. 2011336(3):881-890. Biochemical, pharmaceutical and therapeutic properties of long-acting lithocholic acid derivatized exendin-4 analogs. Chae SY, Jin CH, Shin JH, et al. J Control Release. 2010142(2):206-13. Importance of intermolecular interaction on the improvement of intestinal therapeutic peptide/protein absorption using cell-penetrating peptides. Kamei N, Morishita M, Takayama K. J Control Release. 2009136(3):179-86. Gene therapy for diabetes: metabolic effects of helper-dependent adenoviral exendin 4 expression in a diet-induced obesity mouse model. Samson SL, Gonzalez EV, Yechoor V, Bajaj M, Oka K, Chan L. Mol Ther. 200816(11):1805-12.

Related Research Products & Support

For complementary laboratory workflows, explore related items in our catalog: prepro-Spexin (36-58) (Human) – EIA Kit, SPAG11c (26-58) (Rat) EIA Kit, and Spadin (Human) – EIA Kit available through Phoenix Peptide. Guaranteed for quality assurance and analytical precision.